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Objective: An analysis of the genes involved in both osteoporosis and modifications of the
jawbone, through text mining, using a web search tool, of information regarding gene/
protein interaction.
Design: The final set of genes involved in the present phenomenon was obtained by
expansion-filtering loop. Using a web-available software (STRING), interactions among
all genes were searched for, and a clustering procedure was performed in which only
high-confidence predicted associations were considered.
Results: Two hundred forty-two genes potentially involved in osteoporosis and in modifica-
tions of the jawbone were recorded. Seven ‘‘leader genes’’ were identified (CTNNB1, IL1B,
IL6, JUN, RUNX2, SPP1, TGFB1), while another 10 genes formed the cluster B group (BMP2,
BMP7, COL1A1, ICAM1, IGF1, IL10, MMP9, NFKB1, TNFSF11, VEGFA). Ninety-eight genes had
no interactions, and were defined as ‘‘orphan genes’’.
Conclusions: The expansion of knowledge regarding the molecular basis causing osteopo-
rotic traits has been brought about with the help of a de novo identification, based on the
data mining of genes involved in osteoporosis and in modification of the jawbone. A
comparison of the present data, in which no role was verified for 98 genes that had been
previously supposed to have a role, with that of the literature, in which another 81 genes, as
obtained from GWAS reviews and meta-analyses, appeared to be strongly associated with
osteoporosis, probably attests to a lack of information on osteoporotic disease.
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Generally, osteoporosis is diagnosed when a decrease in bone
mass and bone quality, manifesting itself as bone fragility,
may lead to an increased propensity to fractures resulting
from minimal trauma.1
Even if some forms of osteoporosis have been classified as
primary, divided into ‘‘post-menopausal’’, or type I, and
‘‘senile’’, or type II, and as secondary, manifesting themselves
through specific signs and added symptoms stemming from
further causes,2,3 osteoporotic patients have been generally
screened and followed through a measurement of their bone
mineral density (BMD), which is widely considered as an
indicator of the risk factor for fracture (in conjunction with age
and gender), and which has oriented preventive therapeutic
decisions.4,5
The prevention of fractures obtained through an increase
in bone formation, together with inhibition of bone resorption,
is the ultimate aim of therapy; several strategies are employed,
from modification of diet and lifestyle,6 to the utilization of
medications,7,8 each of which may be quite effective, but also
associated with severe side-effects.9 Moreover, some unrelat-
ed BMD factors may play an important role due to the fact that
most individuals without BMD-defined osteoporosis develop
osteoporotic fractures.1
Despite the common genetic variations, probably each of
the thousands of genetic variants out of a pool of thousands
of genes influences the measured BMD in an infinitesimal
way. Experimental explorations of rare genetic variations,
helpful in improving our overall understanding of the
pathophysiology and pharmacology necessary to prevent
osteoporotic fractures, were started and developed using
different genetic approaches, such as linkage analysis,
candidate and genome-wide association studies (CGAS
and GWAS, respectively), genome-wide sequencing and
functional studies.10–12
The jaw is the secondary target of osteoporosis, even if the
basal part of the jaw remains more intact, especially in the
male mandible, due to its denser cortical base. So alveolar
ridges and maxillary basal parts are mainly exposed to
resorption, due to the high percentage of cancellous struc-
ture.13–15 Alveolar ridge resorption can be induced by several
metabolic bone diseases, such as vitamin D-resistant rickets,16Table 1 – The numbers of the resulting introductory set of gen
Database Research 
GenBank A collection of publicly available annotated nuc
sequences
with coding regions, segments of genomic DNA
ribosomal RNA gene clusters
OMIM A comprehensive, authoritative, and timely com
phenotypes
PubMed Access to all citations from MEDLINE database 
Genatlas Contains relevant information with respect to g
Kegg Database of biological systems, consisting of gen
(KEGG GENES)
SA Bio-Sciences From commercially available DNA-microarrays primary and secondary hyperparathyroidism,17,18 and Paget’s
disease.19,20
For patients who have experienced an intense process of
resorption of the edentulous alveolar ridge, an established
rehabilitation strategy is that of bone reconstruction with
successive insertions of dental implants that support fixed
prostheses. Osteoporosis is not an absolute contraindication
to prosthetic-implant therapy, although the increased risk of
fracture advises for the elimination of the risk factors
associated with it.21 Topic areas regarding osteoporosis, as
summarized by Erdogan et al.21, have been defined, and are
listed as follows: changes in alveolar bone morphology in
osteoporosis, bone repair and turnover in osteoporosis,
alveolar bone regeneration/augmentation associated with
low bone density, patients undergoing ridge augmentation
procedures.
Through a cluster analysis of the genes involved in the
present phenomenon, it was possible to identify certain
genes (the so-called ‘‘leader’’ genes), which can be safely
assumed to play the most essential role in the process as yet
performed for other analyses.22–25 An enormous quantity of
data, including tens of thousands of simultaneous tran-
scripts, had to be carefully sifted through in the highly
complex analysis required in classical microarray experi-
ments: the information obtained regarding the involved set of
genes could then be employed for the design, analysis, and
interpretation of microarray experiments that could be
specifically targeted, in which the transcripts amounted to
only a few hundred.
The primary aim of this study was a de novo identification
of relevant genes in osteoporosis, in particular those linked to
procedures of bone augmentation. Our secondary aim was to
carry out a comparison between resulting primaeval informa-
tion regarding the obtained final set of genes and the newly
putative genes supposed as being associated with osteoporo-
sis, as resulted from several genetic analytical approaches.
2. Materials and methods
2.1. Genes involved in human osteoporosis
A bioinformatic/statistical algorithm, less complex than that
seen in the pristine analysis,23 has been employed and utilizedes sorted by different databases used.
field Resulted genes
(number)
leotide sequences, including mRNA
 with a single gene or multiple genes, and
109
pendium of human genes and genetic 65
and additional life sciences journals 188
ene mapping and genetic diseases 15
etic building blocks of genes and proteins 5
155
Fig. 1 – Data analysis for osteoporosis process: (a) Final map of interactions of 242 genes involved in the present
phenomenon according to STRING. Leader genes and cluster B genes are red. The lines that connect single genes represent
predicted functional associations among proteins, with a high degree of confidence; (b) genes belonging to the leader
cluster in different k-mean clustering experiments with an increasing number of clusters; (c) plot of the gap statistic method
for estimating the number of clusters kˆ; (d) WNL for genes involved in the process. Open circles are cluster B genes. Grey
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Fig. 1. (Continued ).
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was made up of several steps, and for each of them a different
software program was used.
The first step was the establishment of an introductory set
of genes by using the web-available engine Entrez
(www.ncbi.nlm.nih.gov/sites/gquery, that was linked to the
following list of integrated experiment cross-databases:
PubMed, Genbank, Kegg, Omim, Genatlas), and via scanning
of the commercially available DNA-microarray gene lists, as
reported in Table 1.
The search strategy included the following pertinent key
words, obtained from a review paper dealing with osteoporo-
sis and modifications of the jawbone,21 combined using proper
boolean logic operators (AND, OR, NOT) for each search in the
above-mentioned databases:
(1) Gene, human, osteoporosis;
(2) Bone changes;
(3) Bone alveolar regeneration;
(4) Bone alveolar augmentation;
(5) Ridge regeneration procedure;
(6) Ridge augmentation procedure;
(7) 2 OR 3 OR 4 OR 5 OR 6
(8) repair;
(9) turnover;
(10) resorption;
(11) remodelling;
(12) low density;
(13) 8 OR 9 OR 10 OR 11 OR 12
(14) exclusion search strategy: NOT cancer
(15) 1 AND 7 AND 13 AND 14circles are cluster leader genes. Squares are the centroids of the
osteoporosis, sorted by different pathways according to STRING
were exposed. The lines that connect single genes represent pre
degree of confidence: (e) oestrogen endocrine- and vitamin D en
pathway; and (g) RANKL/RANK/OPG pathway. (For interpretation
referred to the web version of this article.)Once a new gene was obtained, its name was verified by
means of the official Human Genome Organization (HUGO)
Gene Nomenclature Committee, or HGNC (available at http://
www.genenames.org/), and the approved gene symbol was
applied erasing previous symbols or aliases. In the second
step, the list of genes was completed; as already described,25
the new gene dataset was expanded with web-available
software STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins: version 8.3 available at http://string-db.org/),
then false positives were filtered by a further search with
PubMed. Consecutive expansion-filtering loops were stopped
at the achievement of the convergence, that is when no new
gene, potentially involved in the present process, was
identified. Before further analysis, the name of each gene of
the final convergence set involved in osteoporosis processes
was newly changed, when necessary, applying that used in the
STRING software.
2.2. Identification of leader genes
For each gene (1, 2, 3, . . .) of the overall final convergence set,
STRING presented all Predicted Functional Partners (a, b, x,
. . .); the STRING Scores represented the level of confidence of
the combined predicted associations for couples 1a, 1b, 1x,
. . . For each gene of the final convergence set, only couples
for which there was a high level of confidence (results with a
score  0.9) were considered, and the scores were extracted,
allowing the obtaining of a numerical variable called
‘‘Weighted Number of Links’’ (WNL), that is, the arithmetical
sum of the high level combined predicted association
scores. cluster groups; Map of interaction for genes involved in
, so that leader genes and/or cluster B genes (both in red)
dicted functional associations among proteins, with a high
docrine-pathway; (f) canonical Wnt/b-catenin signalling
 of the references to color in this figure legend, the reader is
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ry,3 allowing calculations to be performed automatically. A k-
mean algorithm was applied to the input variable WNL, or
‘‘Weighted Number of Links’’, and a partitioning of the overall
dataset of genes into mutually-exclusive clusters was auto-
matically performed.
As was already described, a ‘‘gap statistic’’ method was
applied to the set of data for estimating the optimal number of
clusters kˆ.25 A null reference distribution, required for an
accurate application of the gap statistic method, was
generated, i.e. a uniform distribution throughout the data
dimension, as described by Tibshirani et al.26: reference
datasets were obtained by drawing m samples (m = number
of genes), repeated 5 times.26 Comparisons were performed
between the logarithmic value of the pooled within-cluster
sum of squares around cluster means [log(Wk)] and its
logarithmic expectation according to the null reference
distribution of the data for the clusters from 2 to 16. The
estimate of the number of clusters was given by the value of kˆ
for which log(Wk) fell the farthest from the reference curve.
26
Significant differences among WNLs of cluster groups
obtained by the gap statistic method, were found by
Kruskal–Wallis test (statistical significance at a level of
a = 0.01), verifying the accurate estimate of the number of
clusters.
The first cluster, constituted by the genes with the highest
WNL, was named ‘‘leader’’, or A: so ‘‘leader genes’’ were
assumed to play a leading role in each analyzed process.
According to their prominence, all other ranked gene classes
were named as B, C, D, and so on, until the last gene class, in
which genes that had no identified predicted associations
(WNL = 0) were called ‘‘orphans’’.
Gene score citations (gsc) were also evaluated, as described
in a previous paper,25 by searching for citations in PubMed
using Boolean logic on pertinent key words in all introduced
combinations, as above described, with sequential scoring
strategies: linear weight approach was applied:
 no impact-factor value restriction27 was applied to the
search for citations;
 no discrimination was applied between in vitro or in vivo
data;
 increment of the gene score citation (gsc) by 1 for first
citation in an article, obtained by the search for citations
regarding the analyzed process and published in a journal
cited in the Journal Citation Reports;
 increment of the gene score citation (gsc) by 0.5 in case of the
multiple references, after the initial reference, that incre-
ments gsc by 1, and published by the same group of
researchers (at least two of the same researchers) on a
specific gene.
For each of the upper cluster genes (Leader and B class) a
Specificity Score (SS) was assigned, computed as the ratio
between the number of high level predicted interactions of the
present analysis and the total number of predicted interac-
tions with a higher level of confidence (results with a3 Bioinformatic and Statistics Toolboxes, MatLab 7.0.1, The
MathWorks, Natick, MA.score  0.9) in the whole STRING database. The research
concluded on December 8, 2011.
3. Results
After an initial canvassing using the presented key words, 199
genes potentially involved in osteoporosis disease were
numbered. The searches carried out among the several
databases employed are shown in Table 1. Repetitions of
the same genes found in different databases were erased,
leading, at the moment of the convergence (four expansion-
filtering loops), to 242 genes which constituted the overall final
convergence set.
The STRING map of interactions is represented in Fig. 1A for
the present phenomenon. As the number of clusters
increased, the k-mean clustering gave a number of genes
belonging to the leader cluster 7 (Fig. 1B). The kˆ number of
clusters estimated by the ‘‘Gap statistic’’ method was 9, as
shown in Fig. 1C: excluding the leader- and the orphan-
clusters, the other clusters were named B, C, and so on to H.
For the analyzed process, seven genes belonged to the
cluster of ‘‘leader genes’’ (Fig. 1D and Table 2), and results were
validated by Kruskal–Wallis test, which computed statisti-
cally-significant differences among different clusters: leader
genes, B, C, and so on. Another 10 genes were identified in the
class B group. The ‘‘leader genes’’ were CTNNB1, IL1B, IL6, JUN,
RUNX2, SPP1, TGFB1, while the class B gene group was
constituted by BMP2, BMP7, COL1A1, ICAM1, IGF1, IL10, MMP9,
NFKB1, TNFSF11, VEGFA. Table 2 presents acronyms, official
names, and introduced variables of the upper cluster genes.
The literature was carefully examined in order to determine
which genes showed higher gene score citations (gsc) (Table 3).
Among genes belonging to the two highest clusters (leader
genes and cluster B genes), only 5 were well known to be linked
to osteoporosis and modifications of the jawbone (with a value
of gsc > 100). Among upper cluster genes, all belonging to class
B, only 4 presented relatively low values of gene score citations
(with a value close to 12): BMP7(11), IL10(10.5), ICAM1(10), and
MMP9(5). The specificity scores for each leader and class B gene
are shown in Table 2. In brief, the mean specificity scores were
20.4% and 21.1% for leader and class B genes, respectively.
In Table 4 is presented the overall set of remaining lower
cluster genes (up to H cluster), with the respective gene number,
acronyms, official names, and the primary function as reported
by STRING. The 98 genes that had no interactions, defined as
‘‘orphan genes’’, are ranked in Table 5, in which there are
reported a further 81 genes robustly associated with a reduced
BMD value (resulting from several meta-analysis and reviews),
that had no high level combined predicted association scores
related to any gene from the overall final convergence set.
4. Discussion
The measurement of BMD is still the best predictor of
osteoporotic fractures, although not all individuals experience
loss of BMD with age; the aetiology of osteoporosis is seen to be
multifactorial and in combination with clinical risk factors,
while the rate of bone loss seems to be genetically determined,
Table 3 – Genes classified according to number of citations among 199 genes specifically involved in the osteoporosis
phenomenon.
Gene name Official name Gene score
citations (gsc)
Interaction in the
analyzed phenomenon
Class
PTH Parathyroid hormone precursor >100 10 C
GH1 Somatotropin precursor >100 2 G
TNFRSF11B Tumour necrosis factor receptor superfamily
member 11B precursor (osteoprotegerin)
>100 6 E
TNF Tumour necrosis factor precursor (TNF-a) >100 3 F
TNFSF11 Tumour necrosis factor ligand superfamily
member 11
>100 15 B
CYP19A1 Cytochrome P450 19A1 >100 1 H
IL6 Interleukin-6 precursor >100 21 Leader
CA10 Carbonic anhydrase-related protein 10 >100 0 Orphan
VDR Vitamin D3 receptor >100 4 F
IGF1 Insulin-like growth factor IA precursor >100 17 B
ESR1 Oestrogen receptor >100 8 D
TNFRSF11A Tumour necrosis factor receptor superfamily
member 11A precursor
>100 2 G
TGFB1 Transforming growth factor beta-1 precursor >100 19 Leader
CALCR Calcitonin receptor precursor >100 2 G
BMP2 Bone morphogenetic protein 2 precursor >100 17 B
SHBG Sex hormone-binding globulin precursor >100 1 H
Table 2 – Leader genes and class B genes according to clustering experiments with gene score citations in PubMed,
number of predicted interactions, and Specificity Score for osteoporotic phenomenon.
Gene name Official name Gene
number
Gene score
citations (n)
Interactions in
the analyzed
phenomenon
Interactions in
whole STRING
database (n)
Specificity
score (%)
Leader genes
IL1B Interleukin-1 beta precursor 35 31.5 18 115 15.7
IL6 Interleukin-6 precursor 137 340.5 21 142 14.8
JUN Transcription factor AP-1
(activator protein 1)
139 37.5 22 229 9.6
RUNX2 Runt-related transcription
factor 2
141 78.5 18 55 32.7
SPP1 Osteopontin precursor 187 87.5 19 45 42.2
TGFB1 (CED) Transforming growth factor
beta-1 precursor
201 146.5 19 110 17.3
‘CTNNB1’ Catenin beta-1 208 38 19 181 10.5
Class B genes
BMP2 Bone morphogenetic protein
2 precursor
31 108.5 17 75 22.6
BMP7 Bone morphogenetic protein
7 precursor
64 11 14 47 29.8
COL1A1 Collagen alpha-1 (I) chain
precursor
81 85 14 58 24.1
ICAM1 Intercellular adhesion
molecule 1 precursor
132 10 14 79 17.7
IGF1 Insulin-like growth factor
IA precursor
133 229 17 125 13.6
IL10 Interleukin-10 precursor 134 10.5 13 79 16.5
MMP9 Matrix metalloproteinase-9
precursor
152 5 12 67 17.9
NFKB1 Nuclear factor NF-kappa-B
p105 subunit
158 28.5 15 130 11.5
RANKL (TNFSF11) Tumour necrosis factor ligand
superfamily member 11
222 413 15 33 45.5
VEGFA Vascular endothelial growth
factor A precursor
234 24 17 144 11.8
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Table 4 – All lower cluster genes with respective gene number, cluster group and primary function as reported in STRING.
Gene name Gene
number
Official name Protein primary function in STRING Cluster
RHOA 33 Ras homolog gene family, member A Regulates a signal transduction pathway linking
plasma membrane receptors to the assembly of
focal adhesions and actin stress fibres
C
FADD 108 Fas (TNFRSF6)-associated via death
domain
Apoptotic adaptor molecule that recruits caspase-8
or caspase-10 to the activated Fas (CD95) or TNFR-1
receptors
C
IL1A 136 Interleukin 1, alpha; Produced by activated macrophages, IL-1 stimulates
thymocyte proliferation by inducing IL-2 release,
B-cell maturation and proliferation, and fibroblast
growth factor activity
C
PPARG 179 Peroxisome proliferator-activated
receptor gamma
Receptor that binds peroxisome proliferators such as
hypolipidemic drugs and fatty acids
C
PTH 181 Parathyroid hormone PTH elevates calcium level by dissolving the salts in
bone and preventing their renal excretion
C
STAT1 203 Signal transducer and activator of
transcription 1
Signal transducer and activator of transcription that
mediates signalling by interferons (IFNs)
C
PTHLH 212 Parathyroid hormone-like hormone Neuroendocrine peptide which is a critical regulator
of cellular and organ growth, development,
migration, differentiation and survival and of
epithelial calcium ion transport
C
TRADD 223 TNFRSF1A-associated via death
domain
Adapter molecule for TNFRSF1A/TNFR1 that
specifically associates with the cytoplasmic domain
of activated TNFRSF1A/TNFR1 mediating its
interaction with FADD
C
TRAF6 224 TNF receptor-associated factor 6 Adapter protein and signal transducer that links
members of the tumour necrosis factor receptor
family to different signalling pathways by
association with the receptor cytoplasmic domain
and kinases
C
BMPR1B 30 Bone morphogenetic protein receptor,
type IB
On ligand binding, forms a receptor complex
consisting of two type II and two type I
transmembrane serine/threonine kinases
D
WNT3A 36 Wingless-type MMTV integration site
family, member 3A
Ligand for members of the frizzled family of seven
transmembrane receptors
D
FZD1 37 Frizzled homolog 1 Receptor for Wnt proteins D
LRP6 39 Low density lipoprotein receptor-
related protein 6
Essential for the Wnt/beta catenin signalling
pathway, probably by acting as a coreceptor
together with Frizzled for Wnt
D
ESRRG 41 Oestrogen-related receptor gamma Orphan receptor that acts as transcription activator
in the absence of bound ligand
D
BMP4 65 Bone morphogenetic protein 4 Induces cartilage and bone formation D
COL2A1 83 Collagen, type II, alpha 1 Type II collagen is specific for cartilaginous tissues D
CXCL10 89 Chemokine (C-X-C motif) ligand 10 Chemotactic for monocytes and T-lymphocytes D
ESR1 103 Oestrogen receptor 1 Nuclear hormone receptor D
FASLG 110 Fas ligand (TNF superfamily, member
6)
Cytokine that binds to TNFRSF6/FAS, a receptor that
transduces the apoptotic signal into cells
D
IRAK1 140 Interleukin-1 receptor-associated
kinase 1
Binds to the IL-1 type I receptor following IL-1
engagement, triggering intracellular signalling
cascades leading to transcriptional up-regulation
and mRNA stabilization
D
NFATC1 157 Nuclear factor of activated T-cells,
cytoplasmic, calcineurin-dependent 1;
Plays a role in the inducible expression of cytokine
genes in T-cells, especially in the induction of the
IL-2 or IL-4 gene transcription
D
NR3C1 167 Nuclear receptor subfamily 3, group C,
member 1
Receptor for glucocorticoids (GC) D
SOX9 174 SRY (sex determining region Y)-box 9; Plays an important role in the normal skeletal
development
D
SERPINE1 192 Serpin peptidase inhibitor, clade E
(nexin, plasminogen activator
inhibitor type 1), member 1
This inhibitor acts as ‘bait’ for tissue plasminogen
activator, urokinase, and protein C
D
MEF2C 10 Myocyte enhancer factor 2C Transcription activator which binds specifically to
the MEF2 element present in the regulatory regions
of many muscle-specific genes
E
DKK2 38 Dickkopf homolog 2 Inhibitor of Wnt signalling pathway (Potential) E
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Table 4 (Continued )
Gene name Gene
number
Official name Protein primary function in STRING Cluster
AR 59 Androgen receptor Steroid hormone receptors are ligand-activated
transcription factors that regulate eukaryotic gene
expression and affect cellular proliferation and
differentiation in target tissues
E
CD40LG 75 CD40 ligand Mediates B-cell proliferation in the absence of
co-stimulus as well as IgE production in the
presence of IL-4
E
COL1A2 82 Collagen, type I, alpha 2 Type I collagen is a member of group I collagen
(fibrillar forming collagen)
E
FAS 109 Fas (TNF receptor superfamily,
member 6)
Receptor for TNFSF6/FASLG E
HMOX1 129 Heme oxygenase (decycling) 1; Heme oxygenase cleaves the heme ring at the alpha
methene bridge to form biliverdin
E
MSX2 153 Msh homeobox 2; Probable morphogenetic role E
NOG 161 Noggin; Essential for cartilage morphogenesis and joint
formation
E
NOS3 162 Nitric oxide synthase 3 (endothelial
cell);
Produces nitric oxide (NO) which is implicated in
vascular smooth muscle relaxation through a
cGMP-mediated signal transduction pathway
E
POMC 176 Proopiomelanocortin ACTH stimulates the adrenal glands to release
cortisol
E
SMAD6 197 SMAD family member 6 Antagonist of signalling by TGF-beta (transforming
growth factor) type 1 receptor superfamily members
E
SP1 199 Sp1 transcription factor Transcription factor that can activate or repress
transcription in response to physiological and
pathological stimuli
E
SP7 200 Sp7 transcription factor Transcriptional activator essential for osteoblast
differentiation
E
TGFBR1 209 Transforming growth factor, beta
receptor 1
On ligand binding, forms a receptor complex
consisting of two type II and two type I
transmembrane serine/threonine kinases
E
TNFRSF10A 216 Tumour necrosis factor receptor
superfamily, member 10a
Receptor for the cytotoxic ligand TNFSF10/TRAIL E
TNFRSF11B 218 Tumour necrosis factor receptor
superfamily, member 11b
Acts as decoy receptor for RANKL and thereby
neutralizes its function in osteoclastogenesis
E
TNFRSF1B 220 Tumour necrosis factor receptor
superfamily, member 1B
Receptor with high affinity for TNFSF2/TNF-alpha
and approximately 5-fold lower affinity for
homotrimeric TNFSF1/lymphotoxin-alpha
E
TNFSF10 221 Tumour necrosis factor (ligand)
superfamily, member 10
Cytokine that binds to TNFRSF10A/TRAILR1,
TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3,
TNFRSF10D/TRAILR4 and possibly also to
TNFRSF11B/OPG. Induces apoptosis
E
ALPL 54 Alkaline phosphatase, liver/bone/
kidney
This isozyme may play a role in skeletal
mineralization
F
CALCA 69 Calcitonin-related polypeptide alpha CGRP induces vasodilation F
CYP19A1 93 Cytochrome P450 19, subfamily A1,
polypeptide 1
Cytochromes P450 are a group of heme-thiolate
monooxygenases
F
ESR2 104 Oestrogen receptor 2 (ER beta) Nuclear hormone receptor F
FST 116 Follistatin Binds directly to activin and functions as an activin
antagonist
F
GHRH 124 Growth hormone releasing hormone GRF is released by the hypothalamus and acts on the
adenohypophyse to stimulate the secretion of
growth hormone
F
GSTM1 127 Glutathione S-transferase mu 1 Conjugation of reduced glutathione to a wide number
of exogenous and endogenous hydrophobic
electrophiles
F
GSTT1 128 ENSG00000239562-GSTT1 protein Unknown F
IBSP 131 Integrin-binding sialoprotein Binds tightly to hydroxyapatite F
PDGFA 171 Platelet-derived growth factor alpha
polypeptide
Platelet-derived growth factor is a potent mitogen
for cells of mesenchymal origin
F
SOST 198 Sclerosteosis Negative regulator of bone growth. Interferes with
the Wnt signalling pathway
F
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Table 4 (Continued )
Gene name Gene
number
Official name Protein primary function in STRING Cluster
TNF 215 Tumour necrosis factor (TNF
superfamily, member 2)
Cytokine that binds to TNFRSF1A/TNFR1 and
TNFRSF1B/TNFBR. It is mainly secreted by
macrophages and can induce cell death of certain
tumour cell lines
F
VDR 233 Vitamin D (1,25-dihydroxyvitamin D3)
receptor
Nuclear hormone receptor F
SFRP4 241 Secreted frizzled-related protein 4 Soluble frizzled-related proteins (sFRPS) function as
modulators of Wnt signalling through direct
interaction with Wnts
F
FLT1 28 Fms-related tyrosine kinase 1
(vascular endothelial growth factor/
vascular permeability factor receptor)
Receptor for VEGF, VEGFB and PGF G
APC 34 Adenomatous polyposis coli Tumour suppressor. Promotes rapid degradation of
CTNNB1 and participates in Wnt signalling as a
negative regulator
G
ACVR2B 43 Activin A receptor, type IIB On ligand binding, forms a receptor complex
consisting of two type II and two type I
transmembrane serine/threonine kinases
G
ADAM 17 44 ADAM metallopeptidase domain 17 Cleaves the membrane-bound precursor of
TNF-alpha to its mature soluble form
G
ADH1B 46 Alcohol dehydrogenase 1B (class I),
beta polypeptide
G
ADM 47 Adrenomedullin AM and PAMP are potent hypotensive and
vasodilatator agents
G
ALOX15 53 Arachidonate 15-lipoxygenase Converts arachidonic acid to
15S-hydroperoxyeicosatetraenoic acid
G
CALCR 70 Calcitonin receptor This is a receptor for calcitonin G
CTSK 88 Cathepsin K Closely involved in osteoclastic bone resorption and
may participate partially in the disorder of bone
remodelling
G
DKK1 96 Dickkopf homolog 1 (Xenopus laevis) Inhibitor of Wnt signalling pathway G
ENPP1 99 Ectonucleotide pyrophosphatase/
phosphodiesterase 1
Involved primarily in ATP hydrolysis at the plasma
membrane
G
ESRRA 105 Oestrogen-related receptor alpha Binds to an ERR-alpha response element (ERRE)
containing a single consensus half-site,
50-TNAAGGTCA-30
G
FOXA1 115 Forkhead box A1 Transcription activator for a number of liver genes
such as AFP, albumin, tyrosine aminotransferase,
PEPCK, etc.
G
GH1 123 Growth hormone 1 Plays an important role in growth control G
GSR 126 Glutathione reductase Maintains high levels of reduced glutathione in the
cytosol
G
IL11 135 Interleukin 11 Directly stimulates the proliferation of
hematopoietic stem cells and megakaryocyte
progenitor cells and induces megakaryocyte
maturation resulting in increased platelet production
G
IL1RN 138 Interleukin 1 receptor antagonist Inhibits the activity of IL-1 by binding to its receptor.
Has no IL-1 like activity
G
KIT 142 v-Kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog
This is the receptor for stem cell factor (mast cell
growth factor). It has a tyrosine-protein kinase
activity
G
LEPR 144 Leptin receptor Receptor for obesity factor (leptin). On ligand
binding, mediates signalling through JAK2/STAT3
G
LRP5 148 Low density lipoprotein receptor-
related protein 5
Involved in the Wnt/beta catenin signalling
pathway, probably by acting as a coreceptor together
with Frizzled for Wnt
G
NPY 165 Neuropeptide Y; NPY is implicated in the control of feeding and in
secretion of gonadotrophin-release hormone
G
NQO1 166 NAD(P)H dehydrogenase, quinone 1 The enzyme apparently serves as a quinone
reductase in connection with conjugation reactions of
hydroquinons involved in detoxification pathways
G
PELO 173 Pelota homolog Required for normal chromosome segregation
during cell division and genomic stability
(By similarity)
G
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PPARGC1A 180 Peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha
Transcriptional coactivator for steroid receptors
and nuclear receptors. Greatly increases the
transcriptional activity of PPARG and thyroid
hormone receptor on the uncoupling protein
promoter
G
RHOU 185 Ras homolog gene family, member U Acts upstream of PAK1 to regulate the actin
cytoskeleton, adhesion turnover and increase cell
migration
G
RUNX1 186 Runt-related transcription factor 1 CBF binds to the core site, 50-PYGPYGGT-30, of a
number of enhancers and promoters
G
TANK 206 TRAF family member-associated NFKB
activator
Acts as a regulator of TRAF function by maintaining
them in a latent state
G
TGFBR3 210 Transforming growth factor, beta
receptor III
Binds to TGF-beta. Could be involved in capturing
and retaining TGF-beta for presentation to the
signalling receptors
G
TNFRSF11A 217 Tumour necrosis factor receptor
superfamily, member 11a, NFKB
activator
Receptor for TNFSF11/RANKL/TRANCE/OPGL;
essential for RANKL-mediated osteoclastogenesis
G
TWIST1 230 Twist homolog 1 Probable transcription factor, which seems to be
involved in the negative regulation of cellular
determination and in the differentiation of several
lineages including myogenesis, osteogenesis, and
neurogenesis
G
TYROBP 232 TYRO protein tyrosine kinase binding
protein
Non-covalently associates with activating receptors
of the CD300 family
G
HDAC5 9 Histone deacetylase 5 Responsible for the deacetylation of lysine residues
on the N-terminal part of the core histones (H2A,
H2B, H3 and H4)
H
SOX6 15 SRY (sex determining region Y)-box 6 Transcriptional activator. Binds specifically to the
DNA sequence 50-AACAAT-30. Plays a key role in
several developmental processes, including
neurogenesis and skeleton formation
H
PBX1 21 Pre-B-cell leukaemia homeobox 1 Binds the sequence 50-ATCAATCAA-30. Acts as a
transcriptional activator of PF4 in complex with
MEIS1.
H
ITGA1 23 Integrin, alpha 1 Integrin alpha-1/beta-1 is a receptor for laminin and
collagen
H
IGFBP2 26 Insulin-like growth factor binding
protein 2
IGF-binding proteins prolong the half-life of the IGFs
and have been shown to either inhibit or stimulate the
growth promoting effects of the IGFs on cell culture
H
UGT2B17 40 UDP glucuronosyltransferase 2 family,
polypeptide B17
UDPGTs are of major importance in the conjugation
and subsequent elimination of potentially toxic
xenobiotics and endogenous compounds
H
ACP1 42 Acid phosphatase 1, soluble Acts on tyrosine phosphorylated proteins, low-MW
aryl phosphates and natural and synthetic acyl
phosphates
H
ADRB3 48 Adrenergic, beta-3-, receptor Beta-adrenergic receptors mediate the
catecholamine-induced activation of adenylate
cyclase through the action of G proteins
H
ALDH2 51 ALDH2 – aldehyde dehydrogenase 2
family
Mitochondrial H
ALOX12 52 Arachidonate 12-lipoxygenase Oxygenase and 14,15-leukotriene A4 synthase
activity
H
AOX1 57 Aldehyde oxidase 1 H
ARHGEF12 61 Rho guanine nucleotide exchange
factor (GEF) 12
May play a role in the regulation of RhoA GTPase by
guanine nucleotide-binding alpha-12 (GNA12) and
alpha-13 (GNA13)
H
ARHGEF3 62 Rho guanine nucleotide exchange
factor (GEF) 3
Acts as guanine nucleotide exchange factor (GEF) for
RhoA and RhoB GTPases
H
CASR 71 Calcium-sensing receptor; Senses changes in the extracellular concentration of
calcium ions
H
CBS 73 Cystathionine-beta-synthase H
CD38 74 CD38 molecule Synthesizes cyclic ADP-ribose, a second messenger
for glucose-induced insulin secretion
H
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CLCN7 77 Chloride channel 7 Mediates the exchange of chloride ions against
protons
H
COL3A1 84 Collagen, type III, alpha 1 Collagen type III occurs in most soft connective
tissues along with type I collagen
H
COMT 86 Catechol-O-methyltransferase Catalyzes the O-methylation, and thereby the
inactivation, of catecholamine neurotransmitters
and catechol hormones
H
CXCL2 90 Chemokine (C-X-C motif) ligand 2 Produced by activated monocytes and neutrophils
and expressed at sites of inflammation
H
CYP17A1 91 Cytochrome P450, family 17,
subfamily A, polypeptide 1
Conversion of pregnenolone and progesterone to
their 17-alpha-hydroxylated products and
subsequently to dehydroepiandrosterone (DHEA)
and androstenedione
H
FABP4 107 Fatty acid binding protein 4, adipocyte Lipid transport protein in adipocytes H
GBP1 118 Guanylate binding protein 1,
interferon-inducible
Binds GTP, GDP and GMP H
GGCX 122 Gamma-glutamyl carboxylase Mediates the vitamin K-dependent carboxylation
of glutamate residues to calcium binding
gamma-carboxyglutamate (Gla) residues with the
concomitant conversion of the reduced
hydroquinone form of vitamin K to vitamin
K epoxide
H
HSD11B1 130 Hydroxysteroid (11-beta)
dehydrogenase 1
Catalyzes reversibly the conversion of cortisol to the
inactive metabolite cortisone
H
MEPE 150 Matrix extracellular
phosphoglycoprotein
Seems to play a role in mineralization H
MITF 151 Microphthalmia-associated
transcription factor
Transcription factor for tyrosinase and
tyrosinase-related protein 1
H
MTHFR 155 5,10-Methylenetetrahydrofolate
reductase (NADPH)
Catalyzes the conversion of
5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, a co-substrate for
homocysteine remethylation to methionine
H
NNMT 160 Nicotinamide N-methyltransferase; Catalyzes the N-methylation of nicotinamide and
other pyridines to form pyridinium ions
H
NPPB 163 Natriuretic peptide precursor B; Acts as a cardiac hormone with a variety of
biological actions including natriuresis, diuresis,
vasorelaxation, and inhibition of renin and
aldosterone secretion
H
NPR2 164 Natriuretic peptide receptor
B/guanylate cyclase B
Receptor for atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP), and C-type natriuretic
peptide (CNP)
H
PON1 177 Paraoxonase 1 Hydrolyzes the toxic metabolites of a variety of
organophosphorus insecticides
H
SFRP1 193 Secreted frizzled-related protein 1 Soluble frizzled-related proteins (sFRPS) function as
modulators of Wnt signalling through direct
interaction with Wnts
H
SHBG 194 Sex hormone-binding globulin Functions as an androgen transport protein, but may
also be involved in receptor mediated processes
H
TCIRG1 207 T-cell, immune regulator 1, ATPase,
H + transporting, lysosomal V0
subunit A3
Part of the proton channel of V-ATPases
(By similarity)
H
TIMP2 211 TIMP metallopeptidase inhibitor 2 Complexes with metalloproteinases (such as
collagenases) and irreversibly inactivates them
H
TREM2 225 Triggering receptor expressed on
myeloid cells 2
May have a role in chronic inflammations and may
stimulate production of constitutive rather than
inflammatory chemokines and cytokines
H
WNT10B 238 Wingless-type MMTV integration site
family, member 10B
Ligand for members of the frizzled family of seven
transmembrane receptors. Probable developmental
protein
H
ZNF384 240 Zinc finger protein 384 Transcription factor that seems to bind and regulate
the promoters of MMP1, MMP3, MMP7 and COL1A1
(By similarity)
H
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Table 5 – List of ‘‘orphan’’ genes and new genes strongly associated with osteoporosis, obtained from GWAS reviews and
meta-analyses.
Gene name Gene number Official name
Orphan genes
RTP3 1 Receptor (chemosensory) transporter protein 3
PLCL1 2 Phospholipase C-like 1
C17orf53 3 Uncharacterized protein C17orf53
CRHR1 4 Corticotropin releasing hormone receptor 1
DCDC1 5 Doublecortin domain containing 1
DCDC5 6 Doublecortin domain containing 5
ENSG00000197851 7 Putative uncharacterized protein FLJ42280
STARD3NL 8 STARD3 N-terminal like
IL21R 11 Interleukin 21 receptor
MARK3 12 MAP/microtubule affinity-regulating kinase 3
ZBTB40 13 Zinc finger and BTB domain containing 40
FAM3C 14 Family with sequence similarity 3, member C
CCDC27 16 Coiled-coil domain containing 27
SSU72 17 SSU72 RNA polymerase II CTD phosphatase homolog
ISG15 18 ISG15 ubiquitin-like modifier
RERE 19 Arginine-glutamic acid dipeptide (RE) repeats
LTBP2 20 Latent transforming growth factor beta binding protein 2
CLDN14 22 Claudin 14
FLNB 24 Filamin B, beta
HMGA2 25 High mobility group AT-hook 2
TASP1 27 Taspase, threonine aspartase, 1
DMP1 29 Dentine matrix acidic phosphoprotein 1
FOXC2 32 Forkhead box C2 (MFH-1, mesenchyme forkhead 1)
ADAMTS18 45 ADAM metallopeptidase with thrombospondin type 1 motif, 18
ADRBK2 49 Adrenergic, beta, receptor kinase 2
AHSG 50 Alpha-2-HS-glycoprotein
ANGEL1 55 Angel homolog 1
ANKH 56 Ankylosis, progressive homolog
APOE 58 Apolipoprotein E
ARHGEF1 60 Rho guanine nucleotide exchange factor (GEF) 1
B3GAT3 63 Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)
CA10 66 Carbonic anhydrase X; Does not have a catalytic activity
CA8 67 Carbonic anhydrase VIII
CADM1 68 Cell adhesion molecule 1
CAT 72 Catalase
CEACAM1 76 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary
glycoprotein)
CNP 78 20,30-Cyclic nucleotide 30 phosphodiesterase
CNR2 79 Cannabinoid receptor 2 (macrophage)
COL15A1 80 Collagen, type XV, alpha 1
COL5A2 85 Collagen, type V, alpha 2
CP 87 Ceruloplasmin (ferroxidase)
CYP19A1 92 Cytochrome P450, family 19, subfamily A, polypeptide 1
DBP 94 D site of albumin promoter (albumin D-box) binding protein
DCXR 95 Dicarbonyl/L-xylulose reductase
EBP 97 Emopamil binding protein (sterol isomerase)
ENPEP 98 Glutamyl aminopeptidase (aminopeptidase A)
ARHGAP1 100 Rho GTPase activating protein 1
AXIN1 101 Axin 1
CYLD 102 Cylindromatosis (turban tumour syndrome)
EIF6 106 Eukaryotic translation initiation factor 6
ENPP1 111 ectonucleotide pyrophosphatase/phosphodiesterase 1
ERC1 112 ELKS/RAB6-interacting/CAST family member 1
F2 113 Coagulation factor II (thrombin)
FGFR2 114 Fibroblast growth factor receptor 2
GPR177 117 WLS – G protein-coupled receptor 177
HOXA13 119 Homeobox A13
RARG 120 Retinoic acid receptor, gamma
WNT16 121 Wingless-type MMTV integration site family, member 16
WNT4 125 Wingless-type MMTV integration site family, member 4
WNT5B 143 Wingless-type MMTV integration site family, member 5B
LIPC 145 Lipase, hepatic
LOX 146 Lysyl oxidase
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LRP4 147 Low density lipoprotein receptor-related protein 4
MAPK8IP2 149 Mitogen-activated protein kinase 8 interacting protein 2
MT1G 154 Metallothionein 1G
MTRR 156 5-Methyltetrahydrofolate-homocysteine methyltransferase reductase
NKRF 159 NFKB repressing factor
OSCAR 168 Osteoclast associated, immunoglobulin-like receptor
P2RX7 169 Purinergic receptor P2X, ligand-gated ion channel, 7
PDE4D 170 phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce
homolog)
PDLIM4 172 PDLIM4 – PDZ and LIM domain 4
PLOD1 175 Procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1
PON2 178 Paraoxonase 2
PTN 182 Pleiotrophin
QPCT 183 Glutaminyl-peptide cyclotransferase
RAGE 184 Renal tumour antigen
RXFP2 188 Relaxin/insulin-like family peptide receptor 2
SATB2 189 SATB homeobox 2
SBDS 190 Shwachman-Bodian-Diamond syndrome
SCARA3 191 Scavenger receptor class A, member 3
SLC34A1 195 Solute carrier family 34 (sodium phosphate), member 1
SLPI 196 Secretory leucocyte peptidase inhibitor
SPP2 202 Secreted phosphoprotein 2, 24 kDa
STC2 204 Stanniocalcin 2
SULT2B1 205 Sulfotransferase family, cytosolic, 2B, member 1
TMSL1 213 Thymosin-like 4 (pseudogene)
TMSL2 214 Thymosin-like 4 (pseudogene)
TNFRSF18 219 Tumour necrosis factor receptor superfamily, member 18
TRPM7 226 Transient receptor potential cation channel, subfamily M, member 7
TRPV5 227 Transient receptor potential cation channel, subfamily V, member 5
TRPV6 228 Transient receptor potential cation channel, subfamily V, member 6
TSC22D3 229 TSC22 domain family, member 3
TXNRD1 231 Thioredoxin reductase 1
VPS13B 235 Vacuolar protein sorting 13 homolog B
WASF2 236 WAS protein family, member 2
WIPF1 237 WAS/WASL interacting protein family, member 1
WRN 239 Werner syndrome, RecQ helicase-like
SPTBN1 242 Spectrin, beta, non-erythrocytic 1
Genes robustly associated with BMD on GWAS meta-analyses and reviews
AAAS – Achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A)
ABCF2 – ATP-binding cassette, sub-family F (GCN20), member 2
ADRA1D – Adrenergic, alpha-1D-, receptor
AKAP11 – A kinase (PRKA) anchor protein 11
ALDH7A1 – Aldehyde dehydrogenase 7 family, member A1
C11orf49 – UPF0705 protein C11orf49
C12orf10 – UPF0160 protein MYG1, mitochondrial Precursor
C12ORF23 – UPF0444 transmembrane protein C12orf23
C16ORF38 – Neuronal pentraxin-like protein C16orf38 Precursor
C18ORF19 – Uncharacterized protein C18orf19
C6orf97 – Coiled-coil domain-containing protein C6orf97
CCDC55 – CCDC55
CDK5RAP2 – CDK5 regulatory subunit associated protein 2
CDKAL1 – CDK5 regulatory subunit associated protein 1-like 1
CKAP5 – cytoskeleton associated protein 5
CLCN7 – Chloride channel 7
CPN1 – Carboxypeptidase N, polypeptide 1
DHH – Desert hedgehog homolog
DNM3 – Dynamin 3
EFCAB5 – EF-hand calcium binding domain 5
ERLIN1 – ER lipid raft associated 1
ESPL1 – extra spindle pole bodies homolog 1
FAM9B – Family with sequence similarity 9, member B
FLJ42280 – Putative uncharacterized protein FLJ42280
FOXE1 – Forkhead box E1 (thyroid transcription factor 2)
FOXL1 – Forkhead box L1
FUBP3 – Far upstream element (FUSE) binding protein 3
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GALNT3 – UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosami-
nyltransferase 3 (GalNAc-T3)
GPATCH1 – G patch domain containing 1
IDUA – Iduronidase, alpha-L-
IFT80 – Intraflagellar transport 80 Homolog
INSIG2 – Insulin induced gene 2
JAG1 – Jagged 1 (Alagille syndrome)
KAL1 – Kallmann syndrome 1 sequence
KCNMA1 – Potassium large conductance calcium-activated channel, subfamily M,
alpha member 1
KIAA2018 – KIAA2018
KLHDC5 – kelch domain containing 5
KPNA4 – karyopherin alpha 4 (importin alpha 3)
KPRP – Keratinocyte proline-rich protein
LCE2A – Late cornified envelope 2A
LCE2B – Late cornified envelope 2B
LCE2C – Late cornified envelope 2C
LCE4A – Late cornified envelope 4A
LEKR1 – Putative uncharacterized protein ENSP00000407071
LIN7C – Lin-7 homolog C (C. elegans)
MBL2 – Mannose-binding lectin (protein C) 2, soluble (opsonic defect)
MFSD5 – Major facilitator superfamily domain containing 5
MHC – ENSG00000233904 – HLA class I histocompatibility antigen, alpha chain E
Precursor (MHC class I antigen E)
MPP7 – Membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7)
MTHFR – 5,10-Methylenetetrahydrofolate reductase (NADPH)
NTAN1 – N-terminal asparagine amidase
OSBPL8 – Oxysterol binding protein-like 8
PBX1 – Pre-B-cell leukaemia homeobox 1
PFDN5 – prefoldin subunit 5
PKDCC – Protein kinase domain containing, cytoplasmic homolog
RPS6KA5 – Ribosomal protein S6 kinase, 90 kDa, polypeptide 5
RSPO3 – R-spondin 3 homolog
SHFM1 – split hand/foot malformation (ectrodactyly) type 1
SLC25A13 – Solute carrier family 25, member 13 (citrin)
SMC4 – Structural maintenance of chromosomes 4
SMG6 – Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans)
SOX4 – SRY (sex determining region Y)-box 4
SUPT3H – Suppressor of Ty 3 homolog
TBC1D1 – TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1
TRIM59 – Tripartite motif-containing 59
XKR9 – XK, Kell blood group complex subunit-related family, member 9
ZNF408 – zinc finger protein 408
ENSG00000163286 – Alkaline phosphatase, placental (Regan isozyme)
ENSG00000206292 – Major histocompatibility complex, class II, DO alpha
ERAP1 – Endoplasmic reticulum aminopeptidase 1
FABP3 – Fatty acid binding protein 3, muscle and heart (mammary-derived growth
inhibitor)
FCGR2A – Fc fragment of IgG, low affinity IIa, receptor (CD32)
FKBP2 – FK506 binding protein 2
FLT3 – Fms-related tyrosine kinase 3
FOSB – FBJ murine osteosarcoma viral oncogene homolog B
FTH1 – Ferritin, heavy polypeptide 1
GC – Group-specific component (vitamin D binding protein)
GCM1 – Glial cells missing homolog 1
GDF15 – Growth differentiation factor 15
GRPEL1 – GrpE-like 1, mitochondrial
KL – klotho
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BMD, are seen to contribute to an increased incidence of
fractures.28
From this perspective, osteoporotic clinical phenotyping
that now appears anomalous may be explained through thediscovery of heretofore unknown genetic information. A great
many genes regulating the BMD have been identified by
several genetic approaches, such as linkage analysis (discov-
ering inherited monogenic Mendelian human disease) or
association studies for identifying susceptibility genes, such
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and relating haplotype), or GWAS (genotyping large numbers
of SNPs across the genome, rather than a few candidate
genes), with results that are not perfectly in agreement, and
are sometimes conflicting.11
Numerous genes of at least three metabolic pathways,
these being the estrogenic endocrine pathway, the Wnt/
Catenin pathway, and the RANKL/RANK/OPG pathway, have
been identified as surely associated to osteoporotic traits, and
other genes, instead, have been indicated as being either
promising,29 or robustly associated with BMD,10,28,30 whereas
novel genome-wide-significant loci were supposed to be
strongly associated.1,11,12,31
The preliminary set counted 199 genes; after four expan-
sion-filtering loops based on both the database-search and
microarray gene list scanning, the total number was increased
to 242 genes, showing that STRING expansion- and PubMed
filtering-process, combined into an iterative loop, were
essential to reach the convergence of data and to perform
an accurate analysis. STRING was employed for a combination
of databases regarding direct physical protein–protein inter-
action, experimental gene expression, an active role in
particular metabolic pathways, and indirect functional asso-
ciations.
Although previous studies regarding the cell cycle of
human T lymphocytes, human periodontal disease, and
human bone augmentation/remodelling established that the
numbers of genes in the higher clusters were small, our study
revealed that 17 genes belonged to leader- or B-cluster; this
resulting number of higher cluster genes was in accordance
with the increasing set of genes which were either candidates
to be associated or were found to be robustly associated with
osteoporotic disease.
Most of the discovered ‘‘leader genes’’ were the same as
those involved in the already examined augmentation/
remodelling process25: these were divided into cytokines, such
as interleukins, in particular IL1B, which is produced by
activated macrophages that are important mediators of the
inflammatory response, whereas IL6 has the capacity to
stimulate the development of osteoclasts from their hemato-
poietic precursors,32 or such as the growth factor TGFB1, a
multifunctional peptide that regulates osteoblast chemotaxis,
proliferation and differentiation,33,34 and transcription factors,
like RUNX2, that plays an important role in the maturation of
osteoblasts as well as in both intramembranous and endo-
chondral ossification, with its ‘‘master switch’’ activity,35–37
and JUN, which is involved in regulating gene expression.38
The two adjunctive ‘‘leader genes’’ were CTNNB1, an
essential molecule of the canonical Wnt/b-catenin signalling
pathway, and SPP1, also known as osteopontin, which is
bounded tightly to hydroxyapatite, performing interactions
between the matrix and cells,39 and these two genes resulted
as being associated with BMD at genome-wide-significant
levels in several meta-analyses and reviews.1,11,31
The class B gene group is constituted by genes function-
ally and structurally divided into architectural proteins,
non-collagen matrix molecules, and transcription- and
cytokines/growth-factors. COL1A1 and ICAM1 belong to
the first group. COL1A1 encodes the a-1 chain of type I
collagen, the principal component of bone extracellularmatrix: the studies performed on the effects on BMD of the
three polymorphisms suggested that homozygotes for
different haplotypes showed reduced (haplotype2) or in-
creased (haplotype3) BMD.40 Although COL1A1 has been
extensively studied in osteoporosis,11,12,28 no information
has been obtained in connection to ICAM1, which plays an
active role in the inflammatory process due to contact
between osteoblasts (Obs) and osteoclasts (Ocs), occurring
through the Ob membrane complex, in which the membrane
protein icam1 binds the counter-receptor expressed at the
surface of osteoclasts.41 Also MMP9, an enzyme involved in
degradation of types IV and V collagens, and NFKB1, which
has a prominent role in (antibody) clearance, phagocytosis,
pathogen recognition, and inflammatory response, have
been little examined in more recent meta-analyses and
reviews, even if, together with COL1A1, they have been seen
to be significantly down-regulated in the bone tissue of
osteoporotic women.42,43
The analysis of gene-coding cytokines resumed with 5
growth factors, such as BMP2, BMP7, IGF1, VEGFA and
TNFSF11, and one interleukin, IL10. Interleukin 10, primarily
produced by monocytes and bone morphogenetic proteins
(BMPs) belonging to the group of multifunctional peptides
(TGFb superfamily) that control proliferation and differentia-
tion in many cell types, yielded inconclusive results regarding
an association with osteoporosis44,45 as attested to by the
absence of these two genes from all the more recent reviews
and meta-analyses regarding genome-wide association stud-
ies.1,12,31
Another two genes, although belonging to upper clusters,
appeared not to be associated to osteoporosis after research
performed among genome-wide-significant loci of GWAS
meta-analyses1,12,31: IGF1, encoding a protein similar to
insulin in function and structure, which, interacting with
some variants of ESR2 (Oestrogen Receptor-b), influences the
risk of fracture in postmenopausal women,46 and the growth
factor encoded by VEGFA, that shows several effects on
osteoclast differentiation, angiogenesis, and monocyte/mac-
rophage migration.47
The last class B gene was TNFSF11, a member of the tumour
necrosis factor (TNF) cytokine family, which is a ligand for
osteoprotegerin and functions as a key factor for osteoclast
differentiation and activation.48
The prevention of bone loss in postmenopausal women via
oestrogen replacement therapy has shown that an active role
is played by the oestrogen endocrine system in regulating
bone mass and the occurrence of osteoporosis. The binding
between oestrogen and its receptors, such as the most
extensively studied oestrogen receptors 1 and 2 (ESR1,
ESR2), and oestrogen-related receptors ERR-a (ESRRA) and
ERR-g (ESRRG), resulted in the up-regulation of the expression
of many genes. Experiments and link connection analysis
showed that oestrogen receptors influenced the occurrence of
osteoporosis, both on their own, and by interacting with the
higher cluster genes CTNNB1 and IGF1, as well as with the
leader SPP1 gene for ESRs and for ESRRs, respectively, as is
seen in Fig. 1E.29
As regards the vitamin D endocrine pathway and mainte-
nance of calcium homeostasis, effects of vitamin D are
mediated through its nuclear transcription factor (VDR), but
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ApaI, and TaqI) and BMD were uncertain; even if vitamin D
binding protein (DBP) binds and transports vitamin D, and
mediates bone resorption by directly activating osteoclasts
acting as DBP-macrophage activating factor, the presence of
other genetic and environmental factors was an indispensable
condition for revealing the poor effect of the DBP gene on
fracture risk.49 DBP was an orphan gene, whereas, at third
knot, VDR resulted as connected throughout the oestrogen-
related receptor gamma (ESRRG) to CTNNB1, SPP1, JUN, IL6,
MMP9, and IGF1 (Fig. 1E).
The oestrogen endocrine system and the vitamin D
endocrine pathway seem to be interconnected through the
ESRRG, which is a candidate gene for osteoporosis, due to
consistent associations discovered by recent analysis.50
The mechanism of the canonical Wnt/b-catenin signalling
pathway has been well known, and its importance in the
regulation of bone mass is attested to in the literature.51 The
protein encoded by CTNNB1 (b-catenin) is part of a complex of
proteins that is responsible for transmitting signals through-
out the nuclear transcriptional activity of b-catenin, when the
receptor complex consisting of frizzled family proteins
(encoded by frizzled precursors, FZDs) and low-density
lipoprotein receptor-related protein 5 (LRP5) or LRP6 co-
receptor binds as ligand the Wnt.52 In Fig. 1F, all osteoporo-
sis-associated genes reviewed by Li and co-workers are
presented with all their connections at first knot29; the
presence of the two leader genes, RUNX2, which is that acting
in the proliferation of the osteoprogenitor cell via the
canonical Wnt/b-catenin signalling pathway, and CTNNB1,
gives evidence that the gene encoding b-catenin, as reported
in several GWAS meta-analyses, is strongly associated to
osteoporotic disease.1,11,29,31
Associations between osteoporosis and the genes belong-
ing to RANKL/RANK/OPG pathway were perfectly established.
The three genes of the tumour necrosis factor superfamily,
TNFSF11, TNFRSF11A, and TNFRSF11B, encoded ligand rankl
(receptor activator of nuclear factor-kB ligand), receptor rank
(receptor activator of the nuclear factor-kB), and opg (osteo-
protegerin or tumour necrosis factor receptor superfamily
member 11B). The formation, activation and survival of
multinucleated osteoclasts in normal bone remodelling were
promoted by the normal binding between rankl and rank; opg
acted as a decoy receptor for rankl, and, thereby, neutralized
its function in osteoclastogenesis.48 In Fig. 1G, rankl, rank and
opg are presented with all connections at first knot; most of
the links in Fig. 1G were due to rankl, indicating that this ligand
may be affected by other pathways.
The present in silico study furnished a list of 242 genes
potentially involved in osteoporosis linked to procedures of
jaw bone augmentation. Table 5 reports 98 orphan genes along
with a further 81 genes, obtained from GWAS reviews and
meta-analyses.1,10–12,28,30,31 The majority of these latter also
resulted as ‘‘orphans’’, while the remaining ones are members
of the lowest class, that is, with, at most, just one significant
interaction with present genes belonging to the final conver-
gence set.
The strength of the present analysis, which aimed at the
identification of genes playing a relevant role in osteoporosis
linked to jawbone reconstruction, was based on a combinationof databases regarding direct physical protein–protein inter-
action, experimental gene expression, an active role in
particular metabolic pathways, and indirect functional asso-
ciations, could also be its weakness, owing to possible
‘‘publication bias’’. Some genes of the lower class and,
moreover, the ‘‘orphans’’, for which information is very scant,
could be found to have a significant role in the future, as can be
seen from the wide number of genes for which a strong
association was indicated, albeit with there being a lack of
information regarding their role.
Several microarray experiments were performed in order
to identify differentially expressed genes in osteoporotic bone;
moreover, genes identified and implicated in osteoporosis
pathogenesis were variable in different experimental analy-
ses.53,54 The set for microarray analysis that is commercially
available presents lists specifically addressed to different
pathways (SuperArray Bioscience Corporation: 7320 Executive
Way Frederick, MD 21704 USA), but the roles of several
promising genes (lower class and orphan genes) are not
considered. The lack of information concerning osteoporosis
was borne out by the role played by both associated genes, and
by the numerous old and new ‘‘orphan genes’’, not part of the
known and well-analyzed pathways; further targeted DNA
microarray experiments might help to clarify these still
obscure biomolecular mechanisms.
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